On Nov. 23, the European Commission approved the first gene therapy for the treatment of inherited retinal disease related to a mutation of the RPE65 gene. Luxturna will be authorized in all 28 EU member states as well as Norway, Iceland and Lichtenstein.
The ophthalmology community reacted with great enthusiasm. Not only is an option now available for patients who were blind from an early age, but also an important first step has been made into a new era. Luxturna (voretigene neparvovec, Novartis) is the result of 20 years of (Read more...)
Uncategorized